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http://dx.doi.org/10.1016/j.stemcr.2016.04.005SUMMARYWe previously reported the generation of integration-free induced pluripotent stem cells from adult peripheral blood (PB) with an
improved episomal vector (EV) system, which uses the spleen focus-forming virus U3 promoter and an extra factor BCL-XL (B). Here
we show an 100-fold increase in efficiency by optimizing the vector combination. The two most critical factors are: (1) equimolar
expression of OCT4 (O) and SOX2 (S), by using a 2A linker; (2) a higher and gradual increase in the MYC (M) to KLF4 (K) ratio during
the course of reprogramming, by using two individual vectors to express M and K instead of one. The combination of EV plasmids
(OS +M + K + B) is comparable with Sendai virus in reprogramming efficiency but at a fraction of the cost. The generated iPSCs are indis-
tinguishable from those from our previous approach in pluripotency and phenotype. This improvement lays the foundation for broad
applications of episomal vectors in PB reprogramming.INTRODUCTION
One decade ago, Takahashi and Yamanaka (2006) made a
stunning discovery that mouse somatic cells can be re-
programmed into a pluripotent state after forced expres-
sion of defined factors composed of OCT4 (also known as
POU5F1), SOX2, KLF4, and MYC (also termed c-MYC).
The finding in mouse cells was soon reproduced with hu-
man fibroblasts (Takahashi et al., 2007; Yu et al., 2007).
This breakthrough has changed the landscape of personal-
ized cell therapy, disease modeling, and drug screening.
Fibroblasts are the widely used cellular source for many
reprogramming studies reported in the last decade but
with noticeable limitations (Zhang, 2013). A major draw-
back is that the derivation of a sufficient amount of fibro-
blasts for reprogramming requires a lengthy 2–3 weeks of
in vitro culture. Human fibroblasts are often obtained by
skin biopsy, which is an invasive andnon-sterile procedure.
Of more concern, skin cells bear more mutations due to
environmental insults than cells from inside the body
(Abyzov et al., 2012).
In contrast to dermal fibroblasts, peripheral blood (PB)
has been widely used in medical diagnostics and is the
most accessible resource to procure large quantities of cells.
Compared with human fibroblasts, PB can be obtained
from freshly drawn samples or existing blood stocks. After
drawing blood, gradient centrifugation separates red blood
cells and granulocytes from mononuclear cells (MNCs)
with lower density (Zhang, 2013). The original protocol us-
ing retroviral vectors expressing Yamanaka factors (OCT4,
SOX2, KLF4, and MYC) has been found to be successfulStem
This is an open access artiin many cell types, including hematopoietic cells (Aasen
et al., 2008; Broxmeyer et al., 2011; Loh et al., 2009; Mali
et al., 2008, 2010; Park et al., 2008). Reprogramming of
T cells, a major subpopulation of MNCs, into pluripotency
has been achieved by many laboratories using different ap-
proaches (Loh et al., 2010; Okita et al., 2013; Staerk et al.,
2010) and Tcell reprogramminghas the potential to rejuve-
nate aged T cells for immunotherapy (Nishimura et al.,
2013; Wakao et al., 2013). However, induced pluripotent
stem cells (iPSCs) from non-lymphoid cells may be more
useful, since mature T cells harbor a single T cell receptor
(TCR) after somatic recombination and are unable to regen-
erate the T cell repertoire with unlimited possibilities. In
contrast to mature T cells, hematopoietic progenitors
contain an intact genome and are readily reprogrammable
after ex vivo expansion in conditions that favor the prolif-
eration of myeloid cells or erythroid cells (Agu et al., 2015;
Chou et al., 2011, 2015; Diecke et al., 2015; Dowey et al.,
2012; Hu et al., 2011; Liu et al., 2014; Loh et al., 2009;
Mack et al., 2011; Meng et al., 2012; Merling et al., 2013;
Okita et al., 2013).
For cell replacement therapies, the use of integration-free
iPSCs that bear no exogenous genetic elements is required.
We and other groups have demonstrated that episomal vec-
tors (EV) are capable of reprogramming human somatic
cells, including MNCs, into integration-free iPSCs (Chou
et al., 2011, 2015; Dowey et al., 2012; Meraviglia et al.,
2015; Okita et al., 2013; Su et al., 2013a, 2016; Yu et al.,
2009, 2011). The most commonly used EV is a plasmid
incorporated with two elements from the Epstein-Barr
(EB) virus, origin of viral replication (oriP) and EB nuclearCell Reports j Vol. 6 j 873–884 j June 14, 2016 j ª 2016 The Authors 873
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antigen 1 (EBNA1) (Dorigo et al., 2004). One transfection of
the EV is sufficient for iPSC generation due to oriP/EBNA1-
mediated plasmid retention in mammalian cells, while a
gradual loss of EV during each cell division eventually ren-
ders the iPSC lines to become void of ectopic factors (Chou
et al., 2011; Okita et al., 2013). However, EV-mediated re-
programming was very inefficient, thus potentially risky
factors such as SV40 large T antigen and p53 shRNA were
used in some studies to achieve appreciable efficiency
(Okita et al., 2011; Yu et al., 2009). For reprogramming of
human PB MNCs, the success rate was frustratingly low
without SV40 large T antigen and p53 suppression (Chou
et al., 2011; Dowey et al., 2012). With the use of spleen
focus-forming virus U3 (SFFV), a strong promoter in he-
matopoietic cells, and an additional pro-survival factor
BCL-XL, the reprogramming efficiency of PB MNCs was
increased by 10- to 100-fold (Meng et al., 2012; Su et al.,
2013a, 2016).
In many studies, the reprogramming factors were deliv-
ered individually using monocistronic vectors. However,
due to differences in vector uptake, expression levels of
each gene in each cell are highly variable (Lo et al., 2015).
Since the ratio between the factors is one of most critical
factors for successful reprogramming (Carey et al., 2011;
Kim et al., 2015; Papapetrou et al., 2009), the optimal stoi-
chiometry of the reprogramming factors enhances reprog-
ramming efficiency. To achieve equimolar expression of
multiple proteins, genes can be linked with self-cleaving
2A-like sequences of CHYSEL polypeptides, which are
used by RNA viruses to separate multiple viral genes to be
translated (de Felipe et al., 2006). In this system, cleavage
occurs through ribosomal skipping during translation, re-
sulting in the release of the upstream protein while transla-
tion of the downstreammRNA continues. Commonly used
2A peptides in research are from foot-and-mouth disease
virus (F2A), equine rhinitis A virus (E2A), porcine teschovi-
rus-1 (P2A), and Thosea asigna virus (T2A) (Yang et al.,
2008). As our OS vector linked with E2A can efficiently
reprogram hematopoietic cells (Meng et al., 2012; Su
et al., 2013a, 2016), we use E2A to link two or more genes
to ensure the equimolar expression of several genes in
this study.
In our previous study, using three EV plasmids encoding
OCT4-E2A-SOX2 (OS), BCL-XL (B), and MYC-E2A-KLF4
(MK) (OS + B + MK), we generated 20–30 integration-free
iPSCs from 1 3 106 cultured MNCs or 1 ml of PB (Su
et al., 2013a, 2016). In this study, we report that a simple
change in vector combination by using two EV plasmids
to deliver M and K (M + K) instead of one (MK) leads to
some 100-fold improvement in PB reprogramming. We
further demonstrate that OCT4 and SOX2 linked by E2A
(OS), but not other combinations such as OCT4-E2A-
MYC (OM), OCT4-E2A-KLF4 (OK), and OCT4-E2A-SOX2-874 Stem Cell Reports j Vol. 6 j 873–884 j June 14, 2016E2A-KLF4 (OSK), is the best choice for high-efficiency PB
reprogramming.RESULTS
Expression of MYC and KLF4 in Two Individual
Episomal Vectors instead of One Dramatically
Increases Reprogramming Efficiency
We have reported that the use of three EV plasmids to ex-
press Yamanaka factors and BCL-XL (OS + B + MK) leads
to efficient generation of integration-free iPSCs from PB
MNCs (Su et al., 2013a; Zhang, 2013). In our continuous
efforts to optimize EV-mediated PB reprogramming, we
clonedmultiple vectors to express the five factors monocis-
tronically or polycistronically (Figure 1A). In this study,
frozen or freshly isolated PB MNCs were cultured in
erythroid medium for 6 days to expand erythroid progeni-
tors (Liu et al., 2014). After nucleofection with different
combinations of EV plasmids, cells were cultured in hypox-
ia with Stemline-based serum-free erythroid medium,
which was gradually changed to iPSC induction medium
(Figure 1B). Between 6 and 14 days post-transfection, so-
dium butyrate, an inhibitor of histone deacetylases
(HDACs) (Davie, 2003), was supplemented in the culture
medium to enhance reprogramming (Figure 1B). We acci-
dently found that using two vectors to express MYC and
KLF4 separately leads to a striking increase in reprogram-
ming efficiency (Figure 1C). Using four different PB
samples (PM8, PM9, PM10, and PM11), we obtained 10–
40 alkaline phosphatase (AP)-positive iPSC colonies from
1 3 106 cultured cells with the EV combination of OS +
B + MK, whereas the OS + B + M + K combination gave
rise to 1,000–3,000 iPSC colonies, representing an approx-
imately 100-fold increase (Figure 1D). We also noticed that
small iPSC colonies became visible in OS + B +M+K 1week
after transfection, and the average colony size was much
larger on day 14 in this group than OS + B + MK (Figures
1C and S1A). These data suggest that the OS + B + M + K
combination accelerates reprogramming dynamics and
drastically enhances iPSC generation compared with the
OS + B + MK combination.
Next, we asked if the increase in the number of iPSC
colonies is at the expense of a decrease in stem cell quality.
Staining the bulk population at day 14 with TRA-1-60,
a pluripotency marker, showed no difference in the per-
centage of fully reprogrammed cells (20% for both) (Fig-
ure 1E). Then, we picked ten colonies from each group
and expanded iPSCs in E8 medium for five passages. The
majority of colonies in both conditions can be expanded
long term (data not shown). Fluorescence-activated cell
sorting (FACS) analysis showed that >93% cells expressed
TRA-1-60 or SSEA4, with no discernible differences
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Figure 1. Expression of MYC and KLF4 in
Two Individual Episomal Vectors instead
of One Dramatically Increases the Reprog-
ramming Efficiency of PB MNCs
(A) Schematic diagram of the EV plasmids.
Reprogramming factors were cloned into the
pEV backbone; their expression is driven by
spleen focus-forming virus U3 promoter
(SFFV). 2A (E2A) is a self-cleavage site
derived from equine rhinitis A virus. Wpre,
post-transcriptional regulatory element;
SV40PolyA, polyadenylation signal from
SV40 virus; OriP, EBV origin of replication;
EBNA1, Epstein-Barr nuclear antigen 1,
which plays essential roles in the replication
and persistence of episomal plasmid in in-
fected cells.
(B) Schematic illustration of the overall
experimental design.
(C) Representative images of AP staining at
14 days after nucleofection of PB MNCs with
EV plasmids. Note that the seeding number
in each condition is different.
(D) Substantially increased reprogramming
efficiency with the plasmid combination
OS + B + M + K. Shown are numbers of iPSC
colonies calculated from 1 3 106 PB MNCs
(mean ± SEM, n = 3 independent experi-
ments for each sample). *p < 0.05; ***p <
0.001.
(E) Comparable levels of cells express TRA-1-
60 between two groups. The whole pop-
ulations of cells were analyzed by FACS at
day 14 post-transfection (mean ± SEM, n = 5
independent experiments).
(F) Representative FACS diagrams of iPSCs expressing TRA-1-60 or SSEA4. iPSC colonies derived from indicated combinations of EV plasmids
were analyzed at passage five.
(G) Representative confocal images of iPSC colonies expressing NANOG and OCT4. Scale bar, 100 mm.
See also Figure S1.between groupsOS + B +MK andOS + B +M+K (Figure 1F).
Furthermore, iPSCs derived from the two combinations of
EV plasmids showed expression of iPSC markers NANOG
and OCT4 by confocal microscopy (Figures 1G, S1B, and
S1C). Taken together, these data demonstrate that using
two EV plasmids to express M and K (OS + B + M + K)
instead of one vector (OS + B + MK) increases the reprog-
ramming efficiency of PB MNCs by 100-fold without
affecting iPSC quality.
Dosage Optimization of Each Factor for High-Level
Reprogramming
In our previous study, we showed that in the absence of M,
OS + B + K also induces PB MNCs to pluripotency at a
similar efficiency to that of OS + B + MK (Su et al.,
2013a), but no systemic investigation on factor essentialityof the EV reprogramming systemhas been conducted. Here
we attempted to address this question by omitting one
factor each in the iPSC induction assays. We found that
the absence of M, K, or B led to a substantial decrease in
reprogramming efficiencies by a factor of 100, 10,
and 2–3, respectively (Figures 2A and S2A). Strikingly,
depletion of either O or S from the combination induced
a complete failure in reprogramming (Figures 2A and
S2A). Together, these data demonstrate that all of the five
factors are important for achieving high-level PB MNC
reprogramming.
We further investigated the optimal dosage of each
plasmid for PB reprogramming. In the above experiments,
we used 2 mg of OS, 1 mg of B, 1 mg of M, and 1 mg of K. We
first changed the dosage of OS, and found that halving or
doubling the amount of OS plasmid did not obviouslyStem Cell Reports j Vol. 6 j 873–884 j June 14, 2016 875
Figure 2. Optimal Amount of Each Factor
Is Important for Achieving High-Level Re-
programming
(A) Each of the five factors is important
for efficient reprogramming. Shown are
numbers of iPSC colonies calculated from
1 3 106 PB MNCs (mean ± SEM, n = 3 inde-
pendent experiments).
(B) Dosage effects of reprogramming fac-
tors. Shown are numbers of iPSC colonies
from 1 3 106 PB MNCs transfected with the
indicated amount of each plasmid (mean ±
SEM, n = 3 independent experiments).
(C–E) Summary of dosage effects of BCL-XL
(C), MYC (D), and KLF4 (E) on PB re-
programming. Shown are iPSC colony
numbers from 1 3 106 PB MNCs (mean ±
SEM, n = 3 independent experiments).
*p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S2.affect reprogramming efficiency, whereas a further increase
from 4 mg to 6 mg significantly decreased reprogramming ef-
ficiency by 60% (Figures 2B and S2B). This is likely
because increased amount of plasmids during nucleofec-
tion induced more cell death. When we decreased the
amount of B, M, and K each from 1 mg to 0.5 mg, we
observed a 60%–80%decrease in reprogramming efficiency
(Figures 2B and S2B). To further examine the dosage effects,
we changed the amount of B, M, or K individually. We
found that the optimal dosage for B is 0.25–0.5 mg, which
increases the reprogramming efficiency by 20% (Figures
2C and S2C). In comparison, the optimal dosages for
bothM and K are 1 mg, with either an increase or a decrease
in the plasmid amount leading to a reduction in re-
programming efficiency (Figures 2D, 2E, S2D, and S2E).
Taken together, to achieve high-level PB MNC reprogram-
ming, the optimal vector dosage is 2 mg of OS + 0.5 mg of
B + 1 mg of M + 1 mg of K.876 Stem Cell Reports j Vol. 6 j 873–884 j June 14, 2016Equimolar Expression of OCT4 and SOX2 and the
Ratio of MYC and KLF4 Are the Most Critical Factors
for Achieving High-Level Reprogramming
To systemically examine the effects of different vector
combinations, we expressed the five genes individually or
polycistronically. We observed a striking decrease in the
number of iPSC colonies when OS was expressed by
two vectors (O + S + B + M + K) instead of one (OS + B +
M + K), although the percentages of TRA-1-60 positive cells
in bulk populations showed no significant difference (Fig-
ures 3A and 3C). This finding was reproduced with four in-
dependent PB samples (PM8, PM9, PM10, and PM11);
balanced expression of OS by linking them together with
an E2A sequence led to a 20- to 40-fold increase in reprog-
ramming efficiency compared with the use of two vectors
to deliver O and S (O + S) (Figure 3B). We further examined
the effects of conjugating OCT4 with other factors. Equi-
molar amounts of OCT4 and MYC (OM + B + S + K) led
Figure 3. Equimolar Expression of OCT4
and SOX2 and Ratios of MYC and KLF4
Are the Most Critical Factors for Achieving
High-Level Reprogramming
(A) Representative images of AP staining of
iPSC induction with different combinations
of plasmids. Note that the seeding cell
numbers are different.
(B) Monocistronic expression of O and S
induces a substantial reduction in re-
programming efficiency. Shown are numbers
of iPSC colonies from 1 3 106 PB MNCs
(mean ± SEM, n = 3 independent experi-
ments for each sample).
(C) Comparable levels of cells express TRA-1-
60 in two groups. The whole populations of
cells were analyzed by FACS at day 14 post-
transfection (mean ± SEM, n = 5 indepen-
dent experiments).
(D) Polycistronic expression of O together
with M or K leads to low-efficiency re-
programming. Shown are number of iPSC
colonies from 1 3 106 PB MNCs (mean ±
SEM, n = 3 independent experiments).
(E) Representative images of AP staining of
iPSC from 1 3 106 PB MNCs. MK, pEV-SFFV-
MYC-E2A-KLF4; MKM, pEV-SFFV-MYC-E2A-
KLF4-E2A-MYC.
(F) Increased MYC:KLF4 ratio significantly
increases reprogramming efficiency. Shown
are AP positive colony numbers from 13 106
PB MNCs (mean ± SEM, n = 3 independent
experiments).
*p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S3.to90% reduction in reprogramming efficiency compared
withOS + B +M+K,while bicistronic expression ofO andK
(OK + B +M+ S) only generated a few iPSC colonies (Figures
3D and S3A). Similarly, balanced expression of OSK almost
failed to reprogram PB MNCs to pluripotency (Figures 3D
and S3A). Together, these data demonstrate that bicistronic
expression of OCT4 and SOX2, but not other factor conju-
gations, is of critical importance for achieving high-level PB
MNC reprogramming.
In contrast to balanced expression of O and S, equimolar
expression of M and K (MK) suppresses PB MNC reprog-
ramming (Figures 1C and 1D). To address the potential
mechanism underlying the substantially decreased reprog-
ramming capacity of MK, we analyzed the dynamic
changes of MYC and KLF4 mRNA expression levels after
nucleofection of PB MNCs with OS + B + MK versus OS +
B + M + K during the course of reprogramming. We
observed a steady decrease of MYC expression in both
groups but no obvious differences between the MK andthe M + K group (Figures S3B and S3E). In contrast, we
saw higher KLF4 expression levels in the MK relative to
the M + K group, and the differences increased to 3- to
10-fold between D5 and D13 post-transfection (Figures
S3C and S3F). Plotting the ratio of MYC expression to
KLF4 expression showed that the M:K ratios were >100%
higher in cells transfected with M + K versus MK, and the
differences increased to 5- to 10-fold 1 week post-transfec-
tion (Figures S3D and S3G). These data strongly suggest
that high-level KLF4 expression and thereby lower M:K ra-
tiomay be responsible for the detrimental effects of theMK
vector on reprogramming. To test this possibility,
we cloned an MYC-E2A-KLF4-E2A-MYC (MKM) vector
that encodes two copies of M and one copy of K, thus
increasing the M:K ratio from 1:1 to 2:1. As expected,
doubling of the M:K ratio led to a 4- to 5-fold increase in
reprogramming efficiency (Figures 3E and 3F). However,
reprogramming mediated by OS + B + MKM was still far
less efficient thanOS + B +M + K, likely because, at the laterStem Cell Reports j Vol. 6 j 873–884 j June 14, 2016 877
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D OS+B+M+K iPSC line Figure 4. Characterization of iPSCs Gener-
ated with OS + B + M + K
(A) Dynamics of plasmid copy numbers after
nucleofection. Data are normalized to a one-
copy control (mean ± SEM, n = 4 independent
experiments). *p < 0.05.
(B) Copy numbers of residual EV plasmids in
iPSCs after two, four, or six passages. Specific
primers for EBNA1 and Wpre were used to
amplify episomal vectors. GAPDH was used as
a DNA loading control. UD, undetectable. The
positive lane indicates a one-copy control.
(C) H&E staining of teratomas comprising all
three germ layers. Scale bar, 100 mm.
(D) G-band karyotyping shows a normal
diploid 46, XY male karyotype.stage of reprogramming, KLF4 expression in MKM-trans-
fected cells was still too high to promote proliferation
and progression of partially reprogrammed cells to full plu-
ripotency. Taken together, expression of MYC and KLF4
with two individual vectors can maintain a dynamic ratio
of both factors during the course of reprogramming, lead-
ing to elevated reprogramming efficiency.
Characterization of iPSCs Generated with the
ImprovedEpisomalVectorCombinationOS+B+M+K
After transfection of EV, plasmids are gradually depleted
from the cells, leading to the establishment of integra-
tion-free iPSCs weeks later, but the dynamics of EV deple-
tion from reprogramming PBMNCs has not been reported.
In this study, we were particularly interested in the de-
pletion of MYC and KLF4 plasmids during the course of
reprogramming. Cells were harvested from D2-12 at
2-day intervals for real-time PCR analysis using plasmid-
specific primers. Genomic DNA from untransfected PB
MNCs were used as a negative control, which showed no878 Stem Cell Reports j Vol. 6 j 873–884 j June 14, 2016amplification of the PCR product. We found that there
were more than 100 copies of M or K plasmids per cell in
the first 4 days (Figure 4A). Of interest, this number precip-
itously dropped to less than ten 2 days later (Figure 4A),
which coincided with a rapid cell proliferation. By day 10
post-transfection, there were less than two copies of M or
K plasmids per cell in the bulk population (Figure 4A). We
picked four colonies and tracked the changes in average
copies of total plasmids in each cell. At passage two, only
0.1–0.2 copies per cells were detected in two out of four
clones, while zero copies of plasmids were still present in
four out of four clones at passages four and six (Figure 4B).
These data suggest that EV plasmids are rapidly depleted
from cells, and virtually no ectopic DNA can be detected
at 1 month after transfection. Thus, integration-free iPSCs
can be readily established with this approach.
Having examined the phenotype of generated PB iPSCs
(Figure 1), we further characterized the established inte-
gration-free iPSC lines by teratoma assay and karyotyping.
At 2 months after subcutaneous injection of iPSCs in
immunocompromised mice, we observed teratoma forma-
tion. Histological analysis of the teratomas showed the
composition of tissues from all three primary germ layers
(Figure 4C). To assess the genomic stability of the EV-gener-
ated integration-free iPSCs, an iPSC line was subjected to
karyotype analysis after 20 passages of culture and found
to display a normal karyotype (Figure 4D). These results
demonstrate the non-integrating iPSC lines we generated
are pluripotent and do not harbor obvious chromosomal
abnormalities after long-term culture.
Finally, we compared the efficacy of our improved EV
plasmids with another widely used integration-free reprog-
ramming system, Sendai virus (SeV), which is commer-
cially available at a high cost (>$2,000 per kit). Two weeks
after transfection of the same amount of PB MNCs with
EV or SeV, we observed more iPSC colonies in the EV con-
dition relative to the SeV approach, but the difference did
not reach statistical significance (Figures S1D and S1E). Of
interest, EV-iPSC colonies were largely compact, whereas
SeV-generated colonies appeared more diffused (Fig-
ure S1D). We also found that EV shows a higher success
rate for establishing stable iPSC lines in our culture condi-
tions: 80% picked EV iPSCs can be passaged long term,
whereas 50% of SeV iPSCs spontaneously differentiated
after 2–3 passages (not shown). Together, these results
demonstrate that our improved combination of EV plas-
mids may provide a much better application prospect
than SeV in the generation of integration-free iPSCs from
adult PB.DISCUSSION
Integration-free iPSCs hold great promise for clinical regen-
erative medicine. We have reported that an improved EV
reprogramming system leads to a 10- to 100-fold increase
in PB reprogramming compared with similar methods
developed by other laboratories (Su et al., 2013a). However,
the EV is still less efficient than another popular integra-
tion-free reprogramming vector system, the SeV. After a sys-
temic investigation of vector combinations, we report in
this study that a simple change using two individual vec-
tors to express MYC and KLF4, leads to an additional
100-fold increase in PB reprogramming than we previ-
ously reported (OS +MK + B) (Su et al., 2013a). The marked
improvement can be ascribed to a relatively higher M:K
ratio and lower KLF4 expression during the course of
reprogramming. Another important factor for successful
reprogramming is balanced expression of OCT4 and
SOX2 mediated by a bicistronic vector. Other combina-
tions such as OM + S + K + B, OK + S + M + B, or OSK +
M + B show a significant decrease in reprogramming effi-
ciency compared with OS + M + K + B, highlighting theimportance of vector design. All five factors are critical, in
particular O, S, M, and K. The iPSCs are indistinguishable
from those generated with the previous protocol in expres-
sion of pluripotencymarkers and teratoma-forming ability.
In addition, the iPSC lines show no residual plasmids and a
normal karyotype after long-term culture.
Stoichiometry of reprogramming factors is one of the
most critical factors for successful reprogramming. We
report that equimolar expression of O and S leads to a 20-
to 40-fold increase in reprogramming compared with
monocistronic expression of O and S. This is likely due to
inappropriate ratios in the vast majority of cells transfected
with two vectors encoding O and S. Superficially speaking,
balanced expression of mesoendoderm lineage specifier
OCT4 and ectoderm lineage specifier SOX2 permits reprog-
ramming to iPSCs, whereas unbalanced levels of O and
S attenuate induced reprogramming to pluripotency
(Montserrat et al., 2013; Shu et al., 2013). Mechanistically,
O and S, along with NANOG, constitute the core transcrip-
tional regulatory circuitry in iPSCs and embryonic stem
cells (Boyer et al., 2005; Chen et al., 2008; Kim et al.,
2008). After expression of O and S in transfected cells,
they form a heterodimer (Remenyi et al., 2003) to bind
the canonical motif, in which the SOX2 binding site is
followed immediately by an octamer site (Ng et al., 2012),
synergistically activating pluripotency factors like NANOG
(Kuroda et al., 2005; Rodda et al., 2005). Multiple studies
have also demonstrated that O in concert with S increases
the transcriptional activity of OCT4 (Chew et al., 2005;
Jang et al., 2012). In addition, more than 400 genes ex-
pressed in pluripotent stem cells are bound by both O
and S to promote pluripotency and self-renewal (Boyer
et al., 2005). All these data collectively provide an explana-
tion for the remarkable increase in reprogramming effi-
ciency mediated by equimolar expression of O and S.
MYC is not a pluripotency factor, but it substantially im-
proves reprogramming dynamics, primarily because MYC
accelerates cell proliferation (Sabo et al., 2014; Walz et al.,
2014), providing an opportunity for the somatic genome
to gradually reshape its epigenetic landscape. MYC is crit-
ical at an early stage in cell reprogramming by promoting
the embryonic stem cell-like transcription pattern (Polo
et al., 2012; Sridharan et al., 2009). Similarly to previous re-
ports on fibroblast reprogramming (Nakagawa et al., 2008;
Wernig et al., 2008), MYC increases PB reprogramming
efficiency by 100-fold. We observed partially reprog-
rammed cells in many combinations during the course of
reprogramming. But with the addition of sodium butyrate,
many partially reprogrammed cells were fully converted,
leading to the expression of TRA-1-60 marker in 20%
cells 2 weeks after transfection in all the conditions we
examined (Figures 1E and 3C). The use of MYC as a reprog-
ramming factor was controversial. When a monocistronicStem Cell Reports j Vol. 6 j 873–884 j June 14, 2016 879
integrating vector was used to deliver MYC, reactivation of
the silenced MYC vector in some cells induced tumors in
iPSC-derived animals (Nakagawa et al., 2008; Okita et al.,
2007;Wernig et al., 2008). However, when non-integrating
plasmids were used, MYC was critical for the generation of
high-quality iPSCs that have full developmental ability
(Araki et al., 2011). In addition, we have reported that the
inclusion of MYC in the factor combination does not
significantly increase mutations during reprogramming
(Su et al., 2013b). In this study, a high level of MYC expres-
sion is only observed in the first week of reprogramming
after EV transfection (Figure S3), and no plasmid is detect-
able after four passages. Thus, we argue that the use ofMYC
is advantageous and does not engender obvious adverse ef-
fects in our system.
KLF4 is expressed at very low levels in mature human
iPSCs, whereas low KLF4 expression only gives rise to
partially reprogrammed iPSCs (Nishimura et al., 2014).
Similarly, we observed that a decrease inKLF4 dosage signif-
icantly reduces the reprogramming efficiency, and its omis-
sion leads to an 10-fold drop in PB reprogramming. KLF4
is proposed to be an upstream regulator of larger feedfor-
ward loops containing OCT4 and SOX2 (Kim et al., 2008),
likely becauseKLF4 specifically recruits looping factor cohe-
sin to the OCT4 distal enhancer, facilitating the formation
of a higher-order chromatin structure for maintaining and
inducing pluripotency (Wei et al., 2013).
Strikingly, we found that fixed stoichiometry of M and K
disfavors PB reprogramming.When their stoichiometric re-
lationships are fixed, the reprogramming efficiency is less
impressive, although an increase of M:K from 1:1 to 2:1
leads to a 4-fold increase in reprogramming (Figure 3F).
We also found that high-efficiency reprogramming by
OS + B + M + K is associated with significantly decreased
KLF4 mRNA levels (and high M:K ratios) compared with
the low-efficiency combination OS + B + MK (Figure S3).
These data strongly suggest a differential requirement of
KLF4 during the early and late stages of reprogramming—
high-level expression at the beginning to facilitate cell
transformation, followed by low-level expression to allow
for rapid cell proliferation. It is reported that overexpres-
sion of KLF4 results in the inhibition of DNA synthesis
(McConnell et al., 2007) and activation of anti-proliferative
genes (Rowland and Peeper, 2006), and we also found that
transduction of hematopoietic cells with KLF4 restrains cell
proliferation (not shown). We propose that when M and K
are expressed with two vectors, the optimal M:K ratio is
achieved by self-adaptation of transfected cells—cells
with the right amount of KLF4 and the right ratio of M:K
at the right time are preferentially reprogrammed and
selected for due to proliferative advantage of these cells.
As a result, expression of M and K with two plasmids
instead of one remarkably enhanced reprogramming.880 Stem Cell Reports j Vol. 6 j 873–884 j June 14, 2016Many non-integrating reprogramming strategies have
been investigated over the past 8 years, such as minicircle
plasmids, synthetic mRNA/miRNA, proteins, and small
molecules. However, all these approaches are labor inten-
sive, time consuming, and often inefficient. Recently,
much attention has been focused on two simple vector sys-
tems: SeV and EV. After only one infection or transfection,
dozens or even hundreds of iPSC colonies can be attained
2–3weeks later. Currently, SeV is 10- to 100-timesmore effi-
cient (Schlaeger et al., 2015), whereas EV is more affordable
and does not demand onerous administrative approval.
The cost of EV plasmid preparation and nucleofection re-
agent is $10 per experiment, which is 90% lower than
purchasing the SeV reprogramming kit. Using our
improved EV plasmid combination, which may outcom-
pete SeV in reprogramming efficiency, the primary advan-
tage of SeV vanishes. A recent comparison of EV versus
SeV shows that EV iPSCs have a higher occurrence of aneu-
ploidies (12% versus 5%) (Schlaeger et al., 2015). However,
an alternative explanation of the data is that the increased
abnormalities may have nothing to do with the EV itself,
but rather the use of shP53 in the Yamanaka EV system.
It is most likely that suppression of p53, a guardian of
ploidy (Aylon and Oren, 2011), accounts for the increased
occurrence of aneuploidies. With this in mind, we did not
include shP53 or SV40 big T protein in our system. Instead,
we used an anti-apoptotic factor, BCL-XL, which has no re-
ported link with genetic abnormalities. Accordingly, hu-
man iPSC lines generated with Yamanaka factors together
with BCL-XL display a normal karyotype.
Taken together, the combination of EVs (OS + M + K + B)
meets the dynamic stoichiometry requirements for reprog-
ramming factors, leading to a remarkable enhancement in
the transition of PB MNCs to pluripotency. The improved
EV system is comparable with SeV in reprogramming
efficiency, making the affordable EV approach more att-
ractive and thus eradicating the last barrier to the broad
application of EV plasmids in translational cellular
reprogramming.EXPERIMENTAL PROCEDURES
PB and MNC Isolation
Human PB was obtained from anonymous adult donors with no
identification information available from Tianjin Blood Center
with approval of the local research ethics committee. MNCs were
obtained by standard density gradient centrifugation with Ficoll-
Hypaque (1.077 g/ml) (G&E Healthcare; cat. no. 17-1440-03) at
room temperature as previously described (Zhang, 2013).Episomal Vectors
Inserts of OCT4-E2A-SOX2 (OS), KLF4 (K), BCL-XL (B), MYC-E2A-
KLF4 (MK), OCT4-E2A-MYC (OM), OCT4-E2A-KLF4 (OK), and
OCT4-E2A-SOX2-E2A-KLF4 (OSK) were cloned into an EV plasmid
backbone bearing the SFFV promoter, Wpre, PolyA, oriP, and
EBNA1 elements as described previously (Su et al., 2013a; Zhang,
2013). To drive the expression of two genes, a self-cleaving peptide
sequence from equine rhinitis A virus (E2A) was used to link the
two genes. The sequence of E2A we used is CAG TGT ACT AAT
TAT GCT CTC TTG AAA TTG GCT GGA GAT GTT GAG AGC
AAC CCA GGT CCC. EV plasmids OCT4 (O), SOX2 (S), and MYC
(M) were constructed by inserting the open reading frames of
OCT4, SOX2, and MYC into the EV backbone, respectively.
MYC-E2A-KLF4-E2A-MYC (MKM) was constructed by assembling
MK with the E2A-MYC inert. All the inserts of the cloned vectors
were verified by sequencing.
Reprogramming of PB MNCs to Pluripotency
PB MNCs were cultured in erythroid medium composed of Stem-
line II Hematopoietic Stem Cell Expansion Medium (Sigma;
S0192) supplemented with 100 ng/ml stem cell factor (Peprotech;
300-07), 10 ng/ml interleukin-3 (Peprotech; AF-200-03), 2 U/ml
eryrthropoietin (Peprotech; 100-64), 20 ng/ml insulin growth fac-
tor-1 (Peprotech; 100-11), 1 mM dexamethasone (Sigma; D4902)
and 0.2 mM 1-thioglycerol (Sigma; M6145). After 6 days of cul-
ture, 2 3 106 cells were nucleofected with indicated plasmids
and 5 3 104 to 1 3 106 of cells were plated in gelatin-treated
6-well plates with mitomycin-inactivated murine embryonic
fibroblast feeder cells seeded 1 day before nucleofection. At days
0–2 after nucleofection, PB MNCs were cultured in erythroid
medium. On day 2, we added to each well 2 ml of iPSC induction
medium, composed of Knockout DMEM/F12 (Gibco; 112660-012)
with 13 L-glutamine (Gibco; 25030-081), 13 penicillin/strepto-
mycin (Gibco; 15140-122), 13 non-essential amino acids solution
(Gibco; 11140-050), 50 ng/ml fibroblast growth factor 2 (Pepro-
tech; 100-18B), 13 ITS (Gibco; 41400-045), and 50 mg/ml ascorbic
acid (Sigma; 49752). At day 4, the culture was refreshed with 2 ml
of iPSC induction medium. Starting on day 6, cells were fed with
2 ml of fresh E8 medium (Gibco; A1517001) supplemented with
0.25 mM sodium butyrate every 2 days until day 14. For long-
term culture, iPSCs were maintained in Matrigel-precoated-well
plates and refreshed with E8 medium daily.
Determination of Dynamic Changes of Plasmid Copy
Numbers
PB MNCs after nucleofection were cultured for indicated days and
genomic DNA was extracted. Plasmid copy numbers of MYC and
KLF4 were analyzed by real-time PCR using MYC or KLF4
plasmid-specific primers (Table S1). Genomic DNA from untrans-
fected PB MNCs was used as a negative control. To quantify the
EV copy number, 1.6 pg of M or K plasmid was mixed with 1 mg
of gDNA from untransfected PB MNCs to mimic cells with one
copy of EV plasmid per cell.
Generation of iPSCs by Sendai Viral Vector
Sendai viral reprogramming was performed using a CytoTune-iPS
Reprogramming Kit (Invitrogen; A13780) according to the manu-
facturer’s protocol. After 6 days of culture in erythroid medium, as
detailed above for EV-induced reprogramming, 2 3 105 PB MNCs
were infected with 25 ml each of Sendai viral vector expressingone of the four Yamanaka factors (OCT4, SOX2, KLF4, and
MYC). On the next day, PB MNCs were washed with PBS and
half the amount of cells was plated into 6-well plates with mito-
mycin-inactivatedmurine embryonic fibroblast feeder cells seeded
1 day before. Starting on day 2, PBMNCswere cultured in the same
conditions as EV-induced reprogramming.Statistical Analysis
Data are presented as means and SEM. Two-tailed Student’s t test
was performed. p Values of < 0.05 were considered statistically sig-
nificant. *p < 0.05; **p < 0.01; ***p < 0.001; ns, no significance.
Details of the experimental methods are included in the Supple-
mental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
04.005.
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